Symbiosis has hit a major milestone, producing its first 10,000-vial batch at its new Stirling, UK facility. The batch, made for a long-standing client, supports a cancer immunotherapy currently in Phase III trials.

 

This production milestone positions Symbiosis at the forefront of meeting rising global demand for life-saving medicines.

 

“This first batch of 10,000 vials in our state-of-the-art facility is a pivotal moment for Symbiosis,” said Colin MacKay, CEO. 

 

“It demonstrates the continued evolution of our business, from a start-up to a trusted global partner, and reflects our unwavering commitment to ensuring patients receive the life-changing treatments they depend on. With our expanded capabilities, we are better equipped than ever to support our clients as they advance critical therapies. We are proud to play an integral part in helping innovative treatments move from development to commercial reality.”

 

The FDA-inspected and MHRA-licensed facility underscores Symbiosis’ ability to support clients from clinical trials through to commercial supply. The expansion boosts production capacity, allowing larger batch sizes, accommodating more programs, and providing seamless support for late-stage and commercial launches.